Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial
1. 请及时下载文件确认是否正确, 系统将在 2025-05-04 14:47:11 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
HJ Kang, S Loftus, A Taylor, C DiCristina…
The Lancet …, 2015
thelancet.com
Background Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in combination with other anti-emetic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy in adults, but its efficacy and safety in paediatric patients are unknown. We did this phase 3 trial to examine the safety and efficacy of such treatment in children. Methods In this final analysis of a phase 3, randomised, multicentre, double-blind study, patients aged 6 months to 17 years with a …
